Obesity and beyond

Embracing multi-indication potential during clinical development

The obesity therapeutic marketplace has rapidly embraced multi-indication drug development, following successful label expansion of incretin agonists semaglutide and tirzepatide. Explore the rise of multi-indication drug development across cardiometabolic-related conditions and the strategies driving clinical and commercial success for molecules with broad potential.

Read the whitepaper
obesity_scan_icons
SVG Image

Survey report

How today’s obesity developers are navigating a multi-indication landscape

From January 24 to March 5, 2025, ICON conducted a survey of 155 developers in obesity and related comorbidities. Survey respondents shared their clinical development and commercialisation strategies for molecules with broad clinical and commercial potential, and factors influencing whether or not to pursue multi-indication development of agents in their pipeline.

View the survey report
obesity scan person
SVG Image

A multifaceted risk factor:

Addressing obesity's impact across the disease spectrum

2.8 million people die every year as a result of obesity. At the same time, investment in research and development for obesity therapies is ushering in a new era of effective medications for this disease. Explore the implications of obesity as a risk factor across the disease spectrum, and how this may impact treatment, drug development and clinical trials for obesity.

Read the whitepaper

ICON survey report:

Trends and challenges in obesity research and clinical trials

This survey investigates the opinions, experiences and predictions of a variety of individuals best positioned to provide an overview of current obesity drug and device development — and where it is likely to go in the future. 

Read the survey report

Interdisciplinary expertise in obesity research services

ICON’s highly experienced clinical and therapeutic teams have expertise in conducting trials across a wide range of therapeutic areas including obesity, diabetes, cardiometabolic disorders and hepatology including MASH.

Explore ICON's obesity clinical trial services